1.Exploration of Training System for Visiting Physicians in Department of Rare Diseases
Jiayuan DAI ; Jing XIE ; Jingjing CHAI ; Yueying MAO ; Chunlei LI ; Yaping LIU ; Jin XU ; Min SHEN ; Shuyang ZHANG
JOURNAL OF RARE DISEASES 2026;5(1):112-116
The construction of a training system for visiting physicians in the department of rare diseases in China is an important measure to improve the overall diagnosis and treatment capacity for rare diseases and address the critical challenge of insufficient knowledge and skills among clinicians in practice. This article systematically describes the visiting physician training system established by the Department of Rare Diseases at Peking Union Medical College Hospital. It summarizes the training objectives and positioning, design logic, and learning modules of the system, aiming to provide a reference for the construction of the specialized talent team for rare diseases in China.
2.Interpretation of the Multidisciplinary Expert Consensus on Diagnosi and Treatment of Multiple Lung Cancers by the Chinese Anti-Cancer Association
Jianqi MAO ; Xiaoqiu YUAN ; Jing WANG ; Zhuowei LI ; Yukun CHEN ; Kezhong CHEN
Medical Journal of Peking Union Medical College Hospital 2026;17(3):626-636
With the widespread application of low-dose computed tomography (CT), the detection rate of multiple lung cancers (MLCs) is gradually increasing. The diagnosis and treatment of MLCs have become a major challenge in clinical practice in thoracic surgery and oncology. In April 2025, the Lung Cancer Professional Committee of the China Anti-Cancer Association (CACA) organized multidisciplinary experts from both domestic and international fields to release the first edition of the CACA Expert Consensus on the Diagnosis and Treatment of Multiple Lung Cancers, providing systematic recommendations for the diagnostic system, molecularassessment strategies, and surgical and non-surgical management of MLCs. This article provides a detailed interpretation of the core content of this consensus and, by incorporating the latest research progress in the field, delves into the pathogenesis, precise diagnostic strategies, and individualized treatment pathways for multiple lung cancers, aiming to offer a more comprehensive reference for clinical practice.
3.Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients
Yu LI ; Sheng LI ; Qing LI ; Kai LI ; Jing HAN ; Siyue MAO ; Xiaohong XU ; Zhongzhen SU ; Yanling ZUO ; Shousong XIE ; Hong WEN ; Xuebin ZOU ; Jingxian SHEN ; Lingling LI ; Jianhua ZHOU
Korean Journal of Radiology 2025;26(4):346-359
Objective:
The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) demonstrates high specificity with relatively limited sensitivity for diagnosing hepatocellular carcinoma (HCC) in high-risk patients. This study aimed to explore the possibility of improving sensitivity by combining CT/MRI LI-RADS v2018 with second-line contrast-enhanced ultrasound (CEUS) LI-RADS v2017 using sulfur hexafluoride (SHF) or perfluorobutane (PFB).
Materials and Methods:
This retrospective analysis of prospectively collected multicenter data included high-risk patients with treatment-naive hepatic observations. The reference standard was pathological confirmation or a composite reference standard (only for benign lesions). Each participant underwent concurrent CT/MRI, SHF-enhanced US, and PFB-enhanced US examinations. The diagnostic performances for HCC of CT/MRI LI-RADS alone and three combination strategies (combining CT/ MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or a modified algorithm incorporating the Kupffer-phase findings for PFB [modified PFB]) were evaluated. For the three combination strategies, apart from the CT/MRI LR-5 criteria, HCC was diagnosed if CT/MRI LR-3 or LR-4 observations met the LR-5 criteria using LI-RADS SHF, LI-RADS PFB, or modified PFB.
Results:
In total, 281 participants (237 males; mean age, 55 ± 11 years) with 306 observations (227 HCCs, 40 non-HCC malignancies, and 39 benign lesions) were included. Using LI-RADS SHF, LI-RADS PFB, and modified PFB, 20, 23, and 31 CT/MRI LR-3/4 observations, respectively, were reclassified as LR-5, and all were pathologically confirmed as HCCs. Compared to CT/MRI LI-RADS alone (74%, 95% confidence interval [CI]: 68%–79%), the three combination strategies combining CT/MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or modified PFB increased sensitivity (83% [95% CI: 77%–87%], 84% [95% CI: 79%–89%], 88% [95% CI: 83%–92%], respectively; all P < 0.001), while maintaining the specificity at 92% (95% CI: 84%–97%).
Conclusion
The combination of CT/MRI LI-RADS with second-line CEUS using SHF or PFB improved the sensitivity of HCC diagnosis without compromising specificity.
4.Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients
Yu LI ; Sheng LI ; Qing LI ; Kai LI ; Jing HAN ; Siyue MAO ; Xiaohong XU ; Zhongzhen SU ; Yanling ZUO ; Shousong XIE ; Hong WEN ; Xuebin ZOU ; Jingxian SHEN ; Lingling LI ; Jianhua ZHOU
Korean Journal of Radiology 2025;26(4):346-359
Objective:
The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) demonstrates high specificity with relatively limited sensitivity for diagnosing hepatocellular carcinoma (HCC) in high-risk patients. This study aimed to explore the possibility of improving sensitivity by combining CT/MRI LI-RADS v2018 with second-line contrast-enhanced ultrasound (CEUS) LI-RADS v2017 using sulfur hexafluoride (SHF) or perfluorobutane (PFB).
Materials and Methods:
This retrospective analysis of prospectively collected multicenter data included high-risk patients with treatment-naive hepatic observations. The reference standard was pathological confirmation or a composite reference standard (only for benign lesions). Each participant underwent concurrent CT/MRI, SHF-enhanced US, and PFB-enhanced US examinations. The diagnostic performances for HCC of CT/MRI LI-RADS alone and three combination strategies (combining CT/ MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or a modified algorithm incorporating the Kupffer-phase findings for PFB [modified PFB]) were evaluated. For the three combination strategies, apart from the CT/MRI LR-5 criteria, HCC was diagnosed if CT/MRI LR-3 or LR-4 observations met the LR-5 criteria using LI-RADS SHF, LI-RADS PFB, or modified PFB.
Results:
In total, 281 participants (237 males; mean age, 55 ± 11 years) with 306 observations (227 HCCs, 40 non-HCC malignancies, and 39 benign lesions) were included. Using LI-RADS SHF, LI-RADS PFB, and modified PFB, 20, 23, and 31 CT/MRI LR-3/4 observations, respectively, were reclassified as LR-5, and all were pathologically confirmed as HCCs. Compared to CT/MRI LI-RADS alone (74%, 95% confidence interval [CI]: 68%–79%), the three combination strategies combining CT/MRI LI-RADS with either LI-RADS SHF, LI-RADS PFB, or modified PFB increased sensitivity (83% [95% CI: 77%–87%], 84% [95% CI: 79%–89%], 88% [95% CI: 83%–92%], respectively; all P < 0.001), while maintaining the specificity at 92% (95% CI: 84%–97%).
Conclusion
The combination of CT/MRI LI-RADS with second-line CEUS using SHF or PFB improved the sensitivity of HCC diagnosis without compromising specificity.
5.Current status and trends in the construction of prospective cohorts of healthy populations
Yan XIONG ; Jing MENG ; Kaiyun MAO ; Hongbo JIANG ; Daming CHEN
Chinese Journal of Clinical Medicine 2025;32(5):841-855
Establishing a natural population prospective cohort represents a sophisticated systematic project that spans multiple disciplines and research directions, requiring comprehensive consideration of diverse factors. Both international and domestic practices have accumulated substantial experience and achievements in this field. These prospective cohorts are typically developed through collaborative efforts among research institutions, generating systematic insights into construction backgrounds, objectives, design frameworks, implementation strategies, and management protocols. This study conducts an in-depth investigation into the current status of natural population prospective cohort development globally and domestically, systematically summarizing progress in development history, current status, and research advancements. The findings aim to inform strategic planning in China’s related domains, thereby facilitating the advancement of natural population prospective cohort research.
6.Real world study on antiviral efficacy and safety in patients with normal ALT chronic hepatitis B
Jing WANG ; Jiaqi WANG ; Fang CHEN ; Jie XIA ; Lufeng LI ; Qing MAO
Chongqing Medicine 2025;54(1):138-141
Objective To study the efficacy and safety of antiviral therapy in the patients with normal ALT chronic hepatitis B(CHB).Methods The clinical data of the patients with normal ALT CHB visiting in this hospital from December 2019 to December 2023 were collected.The patients were divided into the low vi-ral load group(HBV DNA<2×106 IU/mL,n=76)and high viral load group(HBV DNA≥2×106 IU/mL,n=10).ETV,TDF and TAF were adopted to conduct the single drug antivirus therapy.The basic informa-tion,demographic characteristics,HBV DNA levels in initial treatment and after 12,24,36,48 weeks of treat-ment,estimated glomerular filtration rate(eGFR)were collected.The rate of complete virological response(CVR)at each time point conducted the statistics for evaluating the effect.The drug safety was evaluated by the eGFR level in 48 weeks of treatment.Results The CVR rates in 12,24,36 weeks of treatment in the low viral load group were 81.6%,94.7%,100.0%and 100.0%respectively,which in the high viral load group were 40.0%,80.0%,80.0%and 80.0%respectively.There was no significant change in eGFR level(109.41±170.57)mL·min-1·1.73 m-2 at 48 weeks of treatment compared with baseline(108.47±110.83)mL·min-1·1.73 m-2(P>0.05).The ALT and creatinine levels during the treatment process in all the patients were not increased.There was no case of drug withdrawal and drug change due to the drug side effects.Conclusion The overall efficacy and safety of ETV,TDF and TAF monotherapy are good in CHB pa-tients with a family history of cirrhosis or liver cancer and normal ALT.The patients with high viral load at baseline are less likely to achieve CVR in 48 weeks of treatment.
7.Efficacy and safety of dye-free submucosal injection solution for gastric endoscopic submucosal dissection
Wan LU ; Yonggang DING ; Ting ZHANG ; Lijuan MAO ; Jing CHEN ; Yuhong ZHOU ; Jun XIAO ; Wenjie LI ; Yaohui WANG ; Qide ZHANG
Chinese Journal of Digestive Endoscopy 2025;42(10):823-827
To evaluate the efficacy and safety of dye-free submucosal injection solution for gastric endoscopic submucosal dissection (ESD), a retrospective cohort study was performed on data of inpatients with early gastric cancer and precancerous lesions who underwent ESD at the Digestive Endoscopy Center of Jiangsu Province Hospital of Traditional Chinese Medicine from January to December 2020. Cases were divided into dye-free submucosal injection solution group (the observation group) and dye-containing solution group (the control group). A total of 108 cases met the eligibility criteria for analysis (39 VS 69). Baseline characteristics were comparable between the two groups ( P>0.05). Compared with the control group, the observation group showed similar median procedure time (30.5 min VS 35.0 min), median dissection speed (0.3 cm2/min VS 0.4 cm2/min), mean volume of injection solution used (39.2 mL VS 38.8 mL), en bloc resection rate [100.0% (39/39) VS 98.6% (68/69)], and curative resection rate [97.4% (38/39) VS 97.1% (67/69)] (all P>0.05). Postoperative stay was 3.0±0.8 days in the observation group and 3.2±0.8 days in the control group ( t=-0.908, P=0.378). Delayed bleeding occurred in 3 (7.7%) patients VS 2 (2.9%) patients ( P=0.349), and postoperative infection occurred in 3 (7.7%) patients VS 8 (11.6%) patients ( P=0.743), respectively. In gastric ESD, dye-free submucosal injection solution demonstrates efficacy comparable with dye-containing solution and does not appreciably increase the incidence of intraoperative or postoperative complications.
8.Association of thoracic aortic calcification with autonomic nervous system function in patients undergoing peritoneal dialysis
Jing WANG ; Xinyi FU ; Yaoyu HUANG ; Yujun QIAN ; Hongqing CUI ; Li ZHANG ; Ningning WANG ; Haibin REN ; Hongwu CHEN ; Huijuan MAO
Chinese Journal of Nephrology 2025;41(5):332-340
Objective:To investigate the relationship between thoracic aortic calcification (TAC) and autonomic nervous system (ANS) function in patients receiving continuous ambulatory peritoneal dialysis (CAPD).Methods:It was a cross-sectional study. The CAPD patients with dialysis duration >6 months between January and December 2022 were retrospectively enrolled. The baseline clinical data, heart rate variability (HRV) data such as standard deviation of all normal to normal intervals (SDNN), root mean square of successive differences between adjacent normal-to-normal intervals (RMSSD), high frequency (HF), very low frequency (VLF), low frequency (LF), LF/HF, acceleration capacity (AC) and deceleration capacity (DC), and skin sympathetic nerve activity (SKNA) were collected. TAC was defined as TAC score (TACS) >100 AU. The patients were divided into TACS >100 AU group and TACS≤100 AU group based on whether the thoracic aorta was calcified. The differences of those data between the two groups were compared. Logistic regression model was used to analyze the related factors of TAC. Spearman correlation analysis method was used to analyze the correlation between peripheral blood neuropeptide Y, ANS parameters, average amplitude SKNA (aSKNA) and TACS. Cox regression model was used to analyze the risk factors of all-cause mortality in patients with CAPD.Results:The study included 106 CAPD patients with 50 males (47.2%), age of (46.04±11.10) years and dialysis duration of (41.55±30.52) months. TACS>100 AU group exhibited significantly lower heart rate ( t=2.015, P=0.046), DC ( t=2.131, P=0.035), LF/HF ( Z=3.332, P<0.001) and ln(LF/HF) ( t=3.326, P=0.001), and higher AC ( t=-2.392, P=0.019) than TACS≤100 AU group. Multivariate logistic regression analysis results showed that after adjusting for age and eosinophil count, lnVLF ( OR=0.66, 95% CI 0.45-0.98, P=0.038), lnLF ( OR=0.69, 95% CI 0.49-0.97, P=0.032), DC ( OR=0.79, 95% CI 0.64-0.99, P=0.039) and AC ( OR=1.32, 95% CI 1.04-1.68, P=0.021) were independently correlated with the risk of TAC. Spearman correlation analysis showed that neuropeptide Y level in peripheral blood was correlated with aSKNA ( r=0.23, P=0.017), lnSDNN ( r=-0.20, P=0.036) and TACS ( r=0.19, P=0.048). During the follow-up period of (25.8±4.2) months, 5 patients (4.72%) died, including 1 patient in the TACS≤100 AU group and 4 patients in the TACS>100 AU group. Compared with the survival group, the death group had higher TACS ( Z=-2.262, P=0.024) and lower LF/HF ( Z=-2.750, P=0.006). Cox regression analysis results showed that increased ln(LF/HF) was an independent influencing factor for all-cause mortality in CAPD patients ( HR=0.22, 95% CI 0.05-0.83, P=0.026). Conclusions:HRV parameters (lnVLF, lnLF, AC and DC) of CAPD patients are independently associated with TAC. The dysfunction of ANS in CAPD patients (especially the decreased vagus nerve activity) may promote TAC.
9.Multidisciplinary team-based real-world study of patients with hepatitis B-related liver cancer
Huimin LIU ; Shilian LI ; Lijian RAN ; Jing WANG ; Wenting CHEN ; Baoyan XU ; Wenting TAN ; Jie XIA ; Qing MAO
Chinese Journal of Experimental and Clinical Virology 2025;39(4):403-410
Objective:To investigate the clinical characteristics of patients with hepatitis B virus(HBV)-related primary hepatocellular carcinoma(HCC)who were treated in a multidisciplinary team(MDT)for liver cancer,so as to provide a basis for clinical optimization of the diagnosis and treatment of patients with chronic hepatitis B(CHB).Methods:A retrospective analysis was performed for 482 HBV-related HCC patients who were treated with HCC-MDT every Thursday afternoon in The First Affiliated Hospital of the Army Medical University from January 2022 to May 2024,aged 18-87(55.54±10.84)years,86.93%(419/482)males and 13.07%(63/482)females. According to the different underlying liver diseases at the time of initial medical treatment and the different prognostic outcomes at the later follow-up,the differences in clinical characteristics between groups under different conditions were compared and analyzed,and the influencing factors of HCC prognosis were understood by Logistic regression analysis. Results:At the time of MDT presentation,the differences in HBeAg status( χ2=6.311 ,P=0.043),γ-glutamyl traspeptidase(GGT)( Z=6.277, P=0.043),alkaline phosphatase(ALP)( Z=7.236 ,P=0.027),and model for end-stage liver disease(MELD)scores( Z=6.111, P=0.047)among patients with different underlying liver diseases were statistically significant. At follow-up,6.75%(11/163)of HBV-related HCC patients who presented to MDT had a family history of HCC,and their cumulative mortality rate was as high as 60.8%(205/337)at least for 1 year. Mulitivariate Logistic regression analysis showed that different underlying liver disease at the time of initial medical treatment,HBV DNA replication level,MELD score and choice of anti-cancer treatment regimen were the influencing factors for the prognosis of HCC(all P<0.05). The worse the degree of cirrhosis at the initial presentation,the higher the level of HBV DNA replication,and the higher the MELD score,the worse the prognosis for HCC. Conclusion:Advancing the diagnosis and treatment of CHB,maximizing the inhibition of HBV DNA replication,reducing the MELD score,and optimizing the anti-cancer treatment regimen can reduce the mortality rate of HBV-related HCC.
10.The predictive value of serum β2M level for prognosis in exacerbated COPD and the results of when it is compared with other inflammatory markers
Wenping MAO ; Qian HAN ; Fengwei JIAO ; Jing WANG ; Kewu HUANG
Journal of Capital Medical University 2025;46(4):718-723
Objective To investigate the prognostic role of serum beta 2-microglobulin(β2M)as a systemic inflammatory biomarker in hospitalized patients with exacerbation of COPD,compared with other inflammatory biomarkers.Methods We retrospectively analyzed hospitalized patients with exacerbated COPD as the first diagnosis at Beijing Chao-Yang hospital,P.R.China,from December 31,2012 to December 28,2017.Serum β2M levels,laboratory and clinical indexes were measured or collected on admission,and all patients were followed up for 90 days.The prognostic performance of β2M was compared with the neutrophils-lymphocytes ratio(NLR),C-reactive protein values(CRP)and white blood cell(WBC)using MedCalc.Results For 30-day mortality,β2M,NLR,and CRP showed significant predictive value(all P<0.001)and were better than WBC(P=0.044,0.003 and 0.030,respectively)in hospitalized patients with exacerbated COPD,while WBC had no predictive significance.For 90-day mortality,β2M,NLR,CRP,and WBC were all statistically significant,but only NLR outperformed WBC(P=0.004).No significant differences were observed among β2M,NLR,and CRP.Conclusion As a systemic inflammatory biomarker,serum β2M was a useful prognostic biomarker for short-term death in hospitalized patients with COPD exacerbations.It performed slightly better than NLR and CRP for 30-day mortality prediction and slightly superior to CRP and slightly inferior to NLR for 90-day mortality prediction.

Result Analysis
Print
Save
E-mail